Curative Effect of Recombinant Human Brain Natriuretic Peptide for Injection Combined with Furosemide in the Treatment of Refractory Heart Failure and the Influence on Cardiac Function, Blood Gas Indexes Serum NT-pro BNP and PCT Levels
JIANG Zhuo, ZHOU Jie, YANG Aixiang, et al
Suzhou Hospital Affiliated to Nanjing Medical University, Jiangsu Suzhou 215000, China
Abstract：Objective: To investigate the effect of recombinant human brain natriuretic peptide for injection combined with furosemide in the treatment of refractory heart failure, and the influence on cardiac function, blood gas indexes, serum N-terminal pro-brain natriuretic peptide (NT-pro BNP) and procalcitonin (PCT) levels. Methods: The clinical data of 108 cases of refractory heart failure treated in our hospital from January 2018 to December 2021 were retrospectively collected. They were divided into a control group (n=54, furosemide) and an observation group (n=54, furosemide combined with Recombinant Human Brain Natriuretic Peptide for Injection) by different medication methods. Clinical effects, cardiac function, blood gas indexes, serum NT-pro BNP and PCT levels were compared between the two groups. Results: The treatment response rate in the observation group (94.44%) was higher than that in the control group (81.48%) (P<0.05). The values of stroke volume left ventricular ejection fraction, left ventricular end-systolic diameter, and left ventricular end-diastolic diameter in the observation group before and after treatment were higher than those in the control group(P<0.05). The differences in arterial partial pressure of oxygen (PaO2), arterial partial pressure of carbon dioxide (PaCO2), and pH values in the observation group before and after treatment were higher than those in the control group (P<0.05). The differences in serum NT-pro BNP and PCT levels in the observation group before and after treatment were higher than those in the control group(P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion: Recombinant human brain natriuretic peptide for injection combined with furosemide is effective in the treatment of refractory heart failure, which can effectively improve the patient's cardiac function and blood gas indexes, and regulate serum NT-pro BNP and PCT levels.
姜卓, 周洁, 杨爱祥, 陶唯益, 王耀东. 新活素注射液联合速尿治疗难治性心力衰竭疗效及对心功能血气指标和血清NT-pro BNP PCT水平的影响[J]. 河北医学, 2023, 29(3): 402-406.
JIANG Zhuo, ZHOU Jie, YANG Aixiang, et al. Curative Effect of Recombinant Human Brain Natriuretic Peptide for Injection Combined with Furosemide in the Treatment of Refractory Heart Failure and the Influence on Cardiac Function, Blood Gas Indexes Serum NT-pro BNP and PCT Levels. HeBei Med, 2023, 29(3): 402-406.
[1] Cappannoli L,Scacciavillani R,Rocco E,et al.Cardiac contractility modulation:a treatment option for patients with refractory heart failure[J].G Ital Cardiol,2021,22(3):212-220. [2] Wang B,Xu H,Li C,et al.Analysis of the effect of lyophilized recombinant human brain natriuretic peptide on endothelial function in patients with acute myocardial infarction[J].Pak Med Sci,2021,37(1):99-103. [3] 张健,邹长虹.《2016年欧洲心脏病学会急慢性心力衰竭诊断与治疗指南》非药物治疗部分解读[J].中国介入心脏病学杂志,2016,24(11):612-615. [4] ariwala P,Jadhav K,Punjani A,et al.Addition of Dapagliflozin,sodium-glucose cotransporter-2 inhibitor to angiotensin receptor blocker-neprilysin inhibitorsnon-responders in patient with refractory heart failure with reduced ejection fraction (ADD DAPA trial)[J].Indian Heart,2021,73(5):605-611. [5] 何建中,卢芳,秦光,等.参麦注射液联合米力农治疗难治性心力衰竭疗效观察[J].中华中医药学刊,2020,38(1):203-206. [6] Nersesian G,Hennig F,Müller M,et al.Temporary mechanical circulatory support for refractory heart failure:the german heart center berlin experience[J].Ann Cardiothorac Surg,2019,8(1):76-83. [7] 付小霞,张淑梅,王贺.参麦注射液联合冻干重组人脑利钠肽治疗急性失代偿期心力衰竭的临床研究[J].中西医结合心脑血管病杂志,2021,19(9):1556-1558. [8] 薛茫,胡桃红.新活素对急性心肌梗死后顽固性心力衰竭患者心功能的影响及临床疗效的观察[J].中国医药导报,2019,16(10):154-156,161. [9] 梁卫章,赵利平,石建平,等.冻干重组人脑利钠肽治疗冠心病心力衰竭疗效及对血流动力学、尿量、心肾功能的影响[J].现代中西医结合杂志,2021,30(20):2236-2238,2242. [10] 高文军.新活素联合左西孟旦治疗慢性心衰急性发作的临床效果[J].中国实用医药,2021,16(33):113-116. [11] Tanaka C,Kurose S,Morinaga J,et al.Serum angiopoietin-like protein 2 and NT-Pro BNP levels and their associated factors in patients with chronic heart failure participating in a phase III cardiac rehabilitation program[J].Int Heart,2021,62(5):980-987. [12] Johnson SA,Rupp AB,Rupp KL,et al.Clinical outcomes and costs associated with procalcitonin utilization in hospitalized patients with pneumonia,heart failure,viral respiratory infection,or chronic obstructive pulmonary disease[J].Intern Emerg Med,2021,16(3):677-686. [13] 王纪良.新活素治疗急性心力衰竭患者的临床疗效与机制分析[J].中国医药指南,2019,17(14):18-20. [14] 姚璐,田国祥,陈艳梅,等.新活素治疗利尿剂抵抗的高龄急性心力衰竭患者的临床观察[J].中国循证心血管医学杂志,2022,14(6):714-716,726.
2023, Vol. 29 
冀公网安备13080202000677号